GCV Asia Congress 2018
Skip Content

24 October 2017

Arsanis seeks IPO arc

The GV-backed immunotherapy developer has filed for a $57.5m initial public offering that will come after $95m of venture financing.

Author: Robert Lavine, News Editor

Arsanis, a US-based immunotherapy developer that counts internet and technology group Alphabet among its investors, has filed to raise up to $57.5m in an initial public offering.